Literature DB >> 20151204

Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.

Cristine Åsberg1, Ola Hjalmarson, Jan Alm, Tommy Martinsson, Johan Waldenström, Christina Hellerud.   

Abstract

Fructose 1,6-bisphosphatase (FBPase) deficiency is an inborn error of metabolism in the gluconeogenetic pathway. During periods of low food intake or infections, a defect in FBPase can result in hypoglycemia, ketonuria and metabolic acidosis. We established a diagnostic system for FBPase deficiency consisting of enzyme activity measurement and mutation detection in calcitriol-stimulated monocytes. In healthy individuals, we showed that FBPase activity is present in monocytes but not in other leukocytes. We describe the clinical course of four individuals from two Swedish families with FBPase deficiency. Family 1: patient 1 died at the age of 6 months after a severe episode with hypoglycemia and acidosis; patients 2 and 3 were followed for >30 years and were found to have a very favorable long-term prognosis. Their FBPase activity from jejunum (residual activity 15-25% of healthy controls), mixed leukocytes (low or normal levels), and calcitriol-stimulated monocytes (no detectable activity) was compared. Mutation analysis showed they were heterozygous for two genetic alterations (c.778G>A; c.881G>A), predicting amino acid exchanges at position p.G260R and p.G294E, originating from their parents. Family 2: patient 4 had no detectable levels of FBPase in stimulated monocytes. A mutation (c.648C>G) predicting a premature stop codon at position p.Y216X was found in one allele and a large deletion of about 300 kb, where the genes FBP2, FBP1 and a part of ONPEP are located, in the other. In conclusion, we present a reliable diagnostic system to verify an FBPase deficiency and find the genetic aberration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151204     DOI: 10.1007/s10545-009-9034-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  13 in total

1.  Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.

Authors:  Peiwei Huangyang; Fuming Li; Pearl Lee; Itzhak Nissim; Aalim M Weljie; Anthony Mancuso; Bo Li; Brian Keith; Sam S Yoon; M Celeste Simon
Journal:  Cell Metab       Date:  2019-11-21       Impact factor: 27.287

2.  Transient pseudo-hypertriglyceridemia: a useful biochemical marker of fructose-1,6-bisphosphatase deficiency.

Authors:  Bushra Afroze; Zabedah Yunus; Beat Steinmann; René Santer
Journal:  Eur J Pediatr       Date:  2013-07-24       Impact factor: 3.183

3.  Fructose 1,6-bisphosphatase deficiency: clinical, biochemical and genetic features in French patients.

Authors:  Elise Lebigot; Anaïs Brassier; Mokhtar Zater; Dilek Imanci; François Feillet; Patrice Thérond; Pascale de Lonlay; Audrey Boutron
Journal:  J Inherit Metab Dis       Date:  2015-01-20       Impact factor: 4.982

4.  Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.

Authors:  Xin Jin; Yunqian Pan; Liguo Wang; Tao Ma; Lizhi Zhang; Amy H Tang; Daniel D Billadeau; Heshui Wu; Haojie Huang
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

5.  Fructose-1,6-bisphosphatase deficiency: a case of a successful pregnancy by closely monitoring metabolic control.

Authors:  Genki Sugita; Hideaki Tsuyoshi; Koji Nishijima; Yoshio Yoshida
Journal:  JIMD Rep       Date:  2014-01-28

6.  Fructose-1,6-bisphosphatase opposes renal carcinoma progression.

Authors:  Bo Li; Bo Qiu; David S M Lee; Zandra E Walton; Joshua D Ochocki; Lijoy K Mathew; Anthony Mancuso; Terence P F Gade; Brian Keith; Itzhak Nissim; M Celeste Simon
Journal:  Nature       Date:  2014-07-20       Impact factor: 49.962

7.  A summary of molecular genetic findings in fructose-1,6-bisphosphatase deficiency with a focus on a common long-range deletion and the role of MLPA analysis.

Authors:  René Santer; Marcel du Moulin; Tatevik Shahinyan; Inga Vater; Esther Maier; Ania C Muntau; Beat Steinmann
Journal:  Orphanet J Rare Dis       Date:  2016-04-21       Impact factor: 4.123

8.  Development of cancer prognostic signature based on pan-cancer proteomics.

Authors:  Weiguo Huang; Jianhui Chen; Wanqing Weng; Yukai Xiang; Hongqi Shi; Yunfeng Shan
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

9.  International practices in the dietary management of fructose 1-6 biphosphatase deficiency.

Authors:  A Pinto; M Alfadhel; R Akroyd; Y Atik Altınok; S M Bernabei; L Bernstein; G Bruni; G Caine; E Cameron; R Carruthers; B Cochrane; A Daly; F de Boer; S Delaunay; A Dianin; M Dixon; E Drogari; S Dubois; S Evans; J Gribben; G Gugelmo; C Heidenborg; I Hunjan; I L Kok; B Kumru; A Liguori; D Mayr; E Megdad; U Meyer; R B Oliveira; A Pal; A Pozzoli; R Pretese; J C Rocha; S Rosenbaum-Fabian; J Serrano-Nieto; E Sjoqvist; C Timmer; L White; T van den Hurk; M van Rijn; H Zweers; M Ziadlou; A MacDonald
Journal:  Orphanet J Rare Dis       Date:  2018-01-25       Impact factor: 4.123

10.  Novel fructose bisphosphatase 1 gene mutation presenting as recurrent episodes of vomiting in an Indian child.

Authors:  A G Sharma; S K Kanwal; V Chhapola; V Kumar
Journal:  J Postgrad Med       Date:  2018 Jul-Sep       Impact factor: 1.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.